A benzochalcone derivative synchronously induces apoptosis and ferroptosis in pancreatic cancer cells

被引:2
作者
Guan, Xiaoqing [1 ,2 ]
Zhao, Bing [1 ]
Guan, Xiaodan [1 ]
Dong, Jinyun [1 ]
Ying, Jieer [1 ,2 ]
机构
[1] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Hangzhou, Zhejiang, Peoples R China
[2] Key Lab Prevent Diag & Therapy Upper Gastrointesti, Hangzhou, Zhejiang, Peoples R China
来源
PEERJ | 2023年 / 11卷
关键词
Pancreatic cancer; Therapeutic agent; Apoptosis; Ferroptosis; PLAC8; GEMCITABINE; ERLOTINIB;
D O I
10.7717/peerj.16291
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background. Pancreatic cancer is a highly aggressive and lethal disease with limited treatment options. In this study, we investigated the potential therapeutic effects of compound KL-6 on pancreatic cancer cells. Methods. The study involved assessing the inhibitory effects of KL-6 on cell proliferation, clonogenic potential, cell cycle progression, apoptosis, migration, and invasion. Additionally, we examined the action mechanism of KL-6 by RNA-seq and bioinformatic analysis and validated by qRT-PCR and western blot in pancreatic cancer cells. Results. Our results demonstrated that KL-6 effectively inhibited the growth of pancreatic cancer cells in a dose-dependent manner. It induced G2/M phase cell cycle arrest and apoptosis, disrupting the cell cycle progression and promoting cell death. KL-6 also exhibited inhibitory effects on cell migration and invasion, suggesting its potential to suppress the metastatic properties of pancreatic cancer cells. Furthermore, KL-6 modulated the expression of genes involved in various cancer-related pathways including apoptosis and ferroptosis. Conclusion. These findings collectively support the potential of KL-6 as a promising therapeutic option for pancreatic cancer treatment. Further research is needed to fully understand the underlying mechanisms and evaluate the clinical efficacy of KL-6 in pancreatic cancer patients.
引用
收藏
页数:20
相关论文
共 36 条
  • [1] Challenges and Opportunities for Pancreatic Cancer Immunotherapy
    Bear, Adham S.
    Vonderheide, Robert H.
    O'Hara, Mark H.
    [J]. CANCER CELL, 2020, 38 (06) : 788 - 802
  • [2] Bockorny B., 2021, CLIN CANCER RES, V27, P5020, DOI [10.1158/1078-0432.CCR-21-0929, DOI 10.1158/1078-0432.CCR-21-0929]
  • [3] PLAC8 Overexpression Promotes Lung Cancer Cell Growth via Wnt/β-Catenin Signaling
    Chen, Wei
    Wu, Junlu
    Wang, Weiwei
    Yu, Li
    Xu, Xianghuai
    [J]. JOURNAL OF IMMUNOLOGY RESEARCH, 2022, 2022
  • [4] Discovery of benzochalcone derivative as a potential antigastric cancer agent targeting signal transducer and activator of transcription 3 (STAT3)
    Dong, Jinyun
    Yang, Jing
    Yu, Wenkai
    Li, Haobin
    Cai, Maohua
    Xu, Jing-Li
    Xu, Han-Dong
    Shi, Yun-Fu
    Guan, Xiaoqing
    Cheng, Xiang-Dong
    Qin, Jiang-Jiang
    [J]. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2022, 37 (01) : 2004 - 2016
  • [5] Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
    Drilon, A.
    Laetsch, T. W.
    Kummar, S.
    DuBois, S. G.
    Lassen, U. N.
    Demetri, G. D.
    Nathenson, M.
    Doebele, R. C.
    Farago, A. F.
    Pappo, A. S.
    Turpin, B.
    Dowlati, A.
    Brose, M. S.
    Mascarenhas, L.
    Federman, N.
    Berlin, J.
    El-Deiry, W. S.
    Baik, C.
    Deeken, J.
    Boni, V.
    Nagasubramanian, R.
    Taylor, M.
    Rudzinski, E. R.
    Meric-Bernstam, F.
    Sohal, D. P. S.
    Ma, P. C.
    Raez, L. E.
    Hechtman, J. F.
    Benayed, R.
    Ladanyi, M.
    Tuch, B. B.
    Ebata, K.
    Cruickshank, S.
    Ku, N. C.
    Cox, M. C.
    Hawkins, D. S.
    Hong, D. S.
    Hyman, D. M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (08) : 731 - 739
  • [6] Injectable Immunotherapeutic Hydrogel Containing RNA-Loaded Lipid Nanoparticles Reshapes Tumor Microenvironment for Pancreatic Cancer Therapy
    Gao, Chao
    Cheng, Keman
    Li, Yao
    Gong, Ruining
    Zhao, Xiao
    Nie, Guangjun
    Ren, He
    [J]. NANO LETTERS, 2022, 22 (22) : 8801 - 8809
  • [7] Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer
    Guan, Xiaoqing
    Yang, Jing
    Wang, Weiyi
    Zhao, Bing
    Hu, Shiyu
    Yu, Dehua
    Yuan, Li
    Shi, Yunfu
    Xu, Jingli
    Dong, Jinyun
    Wang, Jinxin
    Cheng, Xiang-Dong
    Qin, Jiang-Jiang
    [J]. PHARMACOLOGICAL RESEARCH, 2023, 189
  • [8] Pancreatic cancer: Advances and challenges
    Halbrook, Christopher J.
    Lyssiotis, Costas A.
    di Magliano, Marina Pasca
    Maitra, Anirban
    [J]. CELL, 2023, 186 (08) : 1729 - 1754
  • [9] Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib The LAP07 Randomized Clinical Trial
    Hammel, Pascal
    Huguet, Florence
    van Laethem, Jean-Luc
    Goldstein, David
    Glimelius, Bengt
    Artru, Pascal
    Borbath, Ivan
    Bouche, Olivier
    Shannon, Jenny
    Andre, Thierry
    Mineur, Laurent
    Chibaudel, Benoist
    Bonnetain, Franck
    Louvet, Christophe
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (17): : 1844 - 1853
  • [10] Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits
    Heinrich, Stefan
    Lang, Hauke
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (08)